There is a moment that happens in consulting rooms across the country with remarkable regularity. A woman sits down, describes skin changes she cannot explain – tightness that persists despite drinking two litres of water a day, products she has used for decades that now sting on contact, small red bumps that are not quite acne and then says: ‘My GP told me to moisturise more. It’s not working.’
She is right. It is not working. And the reason it is not working is that the advice she received, however well-intentioned is built on a fundamental misread of what is actually happening to her skin.
In perimenopause and menopause, skin does not simply become dry. It becomes biologically altered at a barrier level, a structural level, and an inflammatory level simultaneously. These are three distinct processes, each driven by hormonal change, each requiring a targeted response. A heavier moisturiser addresses none of them.
The biology the beauty industry rarely discusses
To understand why conventional advice fails menopausal skin, it helps to understand what oestrogen actually does — not for reproduction, but for the skin’s structural integrity.
Oestrogen regulates lipid production in the stratum corneum — the outermost layer of the skin — maintaining the lamellar architecture of ceramides, fatty acids, and cholesterol that forms the skin barrier. It supports the synthesis of natural moisturising factors (NMFs), modulates the rate of epidermal cell turnover, and plays a central role in collagen production throughout the dermis. It also exerts a meaningful anti-inflammatory effect on skin tissue.
When oestrogen levels begin to fluctuate in perimenopause and then decline more steadily through to menopause — every one of these functions is compromised. Lipid production drops. The barrier’s lamellar structure becomes disrupted. Transepidermal water loss (TEWL) increases. Epidermal turnover slows. The dermis thins. And a state of chronic low-grade inflammation establishes itself as the new baseline — subclinical, persistent, and largely unaddressed by conventional skin care advice.
This is not ageing in the conventional sense. This is a hormonally mediated biological transition. The distinction matters clinically — and it matters for how we communicate with patients and consumers.
Perimenopause versus menopause: a critical clinical distinction
One of the most consequential errors in menopausal skin care — in both clinical practice and product development is treating perimenopause and menopause as the same skin state. They are not, and conflating them produces the wrong interventions for both groups.
In perimenopause, the defining characteristic is instability. Oestrogen levels fluctuate unpredictably – sometimes sharply – creating a barrier that oscillates between periods of increased sebum production and pronounced dryness, between relative tolerance and acute reactivity. A patient may report that her serum works beautifully one week and causes stinging the next. This is not sensitivity in the clinical sense. It is hormonal volatility, expressed through the barrier.
In menopause, the picture shifts from instability to depletion. With oestrogen now consistently and significantly lower, barrier dysfunction becomes chronic rather than episodic. Lipid production is persistently reduced. TEWL is permanently elevated. Low-grade inflammation is the new resting state. The skin is thinner, less elastic, and structurally more fragile. Not in peaks and troughs, but as a fixed baseline.
The treatment implications are direct: perimenopausal skin needs adaptive, calming strategies that accommodate fluctuation. Menopausal skin needs consistent, restorative protocols anchored in barrier repair. Applying the same formulation logic to both, as the industry largely does, produces sub-optimal outcomes for most women in both groups.
Why products that worked for 20 years suddenly suddenly sting or burn?
The most distressing and least-explained symptom I encounter is sudden intolerance to previously well-tolerated products. Women describe stinging, burning, and flushing from formulations they have used safely for years. The standard response, from both GPs and aestheticians, is to recommend stripping the routine back. This is partially correct, but the reasoning is almost never explained.
What is happening is this: a thinning epidermis and disrupted lipid matrix means topical products are now penetrating significantly more deeply than before. Ingredients that previously interacted primarily with the stratum corneum are now reaching the deeper epidermal and upper dermal layers where they activate TRPV1 pain receptors and inflammatory mediators. The product has not changed. The barrier has. And that barrier can no longer regulate the depth of penetration it once managed effortlessly.
This carries direct implications for formulation. Carriers, penetration enhancers, preservative systems, and fragrance compounds — all typically well-tolerated — carry meaningful risk in a compromised menopausal barrier. Low-irritancy vehicles, fragrance-free formulations, and biomimetic emulsions that integrate into the barrier structure rather than penetrating through it are not luxury considerations. They are clinical necessities.
The inflammatory architecture of menopausal skin
Perhaps the most underappreciated aspect of hormonal skin change is the role of chronic low-grade inflammation. In a hormonally intact skin environment, oestrogen exerts a measurable anti-inflammatory effect at the tissue level. When it declines, this protection is lost — and the consequences extend well beyond surface reactivity.
Matrix metalloproteinases (MMPs) — zinc-dependent enzymes responsible for the controlled remodelling of extracellular matrix proteins including collagen and elastin — become overactivated in an inflammatory environment. Rather than contributing to structural renewal, they accelerate structural degradation. Collagen and elastin are broken down faster than they can be replaced. The dermis thins. Capillary integrity is compromised, contributing to easy bruising and significantly impaired wound healing. This is the mechanism behind the skin fragility my patients describe as ‘tearing from a fingernail scratch.’
The gut-skin axis compounds this further. There is growing clinical evidence that hormonal transitions during perimenopause and menopause alter the gut microbiome in ways that have direct downstream consequences for skin inflammation, barrier permeability, and immune reactivity. Skin presenting with unexplained texture changes, subclinical follicular inflammation, or chronic redness in this life stage cannot be adequately managed through topical intervention alone. Systemic inflammatory load — through nutrition, stress, sleep quality, and microbiome health — is part of the clinical picture and must be part of the treatment conversation.
The correct clinical sequence — and why it is rarely followed
The framework I use in my practice and that underpins the formulation philosophy at Twenty 4 is built on a non-negotiable sequence: barrier stabilisation first, anti-inflammatory support second, targeted actives third. The failure to observe this sequence is the single most common error in menopausal skin management, and it is responsible for the majority of treatment failures I see.
In practice: before any anti-ageing, brightening, or resurfacing strategy is introduced, the barrier must be genuinely stabilised. This requires formulations containing ceramides, fatty acids, and cholesterol in physiologically relevant proportions as functional biomimetic ingredients, not marketing claims. It requires the removal of all potential irritants: fragrance, high-concentration preservatives, penetration enhancers, and overly complex stabiliser systems. And it requires anti-inflammatory support: niacinamide, panthenol, azelaic acid, and other actives with established tolerability profiles in compromised barrier states.
Only once the barrier is stable and inflammation managed should retinoids, exfoliating acids, and higher-potency actives be reintroduced — slowly, systematically, and with the barrier’s structural integrity continuously in view. This approach is not conservative. It is efficient. A properly stabilised skin will respond to treatment actives more effectively, with lower rates of adverse reaction, than one subjected to aggressive intervention from the outset.
A reframe the industry has been avoiding
The conversation around menopausal skin has been dominated, for too long, by symptom management rather than biological understanding. Women are told their skin is ageing. They are sold richer creams and simpler routines. None of this addresses what is actually happening and in many cases, it actively worsens it.
What is actually happening is a hormonally mediated, multi-system biological transition affecting barrier function, inflammatory regulation, structural integrity, microbiome balance, and wound healing simultaneously. It is complex. It is clinically treatable. And it deserves both a clinical vocabulary and a product response that match that complexity.
When women receive that vocabulary, when they understand that their skin is not failing them, but responding rationally to a hormonal environment it has never navigated before the dynamic changes. They become more discerning consumers. They ask better questions. They make better decisions. And they get significantly better outcomes.